Atyr Pharma Inc. (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

LIFE has been the subject of a number of other research reports. BMO Capital Markets set a $8.00 price target on Atyr Pharma and gave the company a “hold” rating in a report on Thursday, October 6th. Citigroup Inc. increased their price target on Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday, August 16th. Finally, JPMorgan Chase & Co. reduced their price target on Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, August 11th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $6.50.

Shares of Atyr Pharma (NASDAQ:LIFE) opened at 2.89 on Wednesday. The firm has a 50-day moving average price of $3.12 and a 200 day moving average price of $3.24. Atyr Pharma has a 52-week low of $2.48 and a 52-week high of $13.26. The stock’s market cap is $68.55 million.

Atyr Pharma (NASDAQ:LIFE) last issued its earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.06. Analysts expect that Atyr Pharma will post ($2.56) earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Atyr Pharma by 120.3% in the second quarter. Vanguard Group Inc. now owns 439,732 shares of the company’s stock worth $1,223,000 after buying an additional 240,101 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Atyr Pharma by 317.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 344,214 shares of the company’s stock worth $957,000 after buying an additional 261,753 shares in the last quarter. BlackRock Advisors LLC increased its position in Atyr Pharma by 14,820.9% in the second quarter. BlackRock Advisors LLC now owns 244,405 shares of the company’s stock worth $679,000 after buying an additional 242,767 shares in the last quarter. Emerald Acquisition Ltd. purchased a new position in Atyr Pharma during the second quarter worth approximately $206,000. Finally, State Street Corp increased its position in Atyr Pharma by 51.8% in the first quarter. State Street Corp now owns 68,285 shares of the company’s stock worth $270,000 after buying an additional 23,290 shares in the last quarter. 44.75% of the stock is currently owned by institutional investors.

About Atyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

5 Day Chart for NASDAQ:LIFE

Receive News & Stock Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related stocks with our FREE daily email newsletter.